大鼠局灶性脑缺血/再灌注模型的制作及经验体会  

Establishment of Local Cerebral Ischemia/Reperfusion Model in Rats and Experience

作　　者：孔卫国[1] 吴晓牧[2] 张昆南[2] 黄刚[2] 张洪连[1] 刘世民[1] 

机构地区：[1]南昌大学研究生院医学部 [2]江西省人民医院神经内科,南昌330006

出　　处：《实用临床医学（江西）》2010年第3期1-3,15,F0003,共5页Practical Clinical Medicine

基　　金：国家科技支撑计划课题(2008BAI68B03)

摘　　要：目的探索大鼠局灶性脑缺血/再灌注模型的制作方法。方法在LongaE.Z.等模型制作方法基础上进行完善和改进,用线栓阻塞SD大鼠右侧大脑中动脉(middle cerebral artery,MCA),实验组60只大鼠2h后再灌注,另外30只大鼠作为假手术对照组。术后2、24h,3、7d大鼠进行神经功能评分和死亡统计,TTC染色对梗死范围进行评价。结果实验组大鼠死亡率达14%,在术后2、24h,3、7d的神经功能评分均明显高于假手术对照组(均P<0.01),TTC染色显示右侧额顶叶、部分颞叶及基底节区缺血损伤。结论通过对大鼠局灶性脑缺血/再灌注模型制作过程中一些细节的完善,该模型重复性、稳定性好,而且制作过程操作简便,成功率高。Objective To explore the method of preparing the model of the focal cerebral ischemia/reperfusion injury in rats.Methods The local cerebral ischemia/reperfusion model in SD rats was established by the modified Longa E.Z.et al.Method.The right middle cerebral artery （MCA） was occluded for 2 hours by intraluminal suture technique and then the reperfusion was performed in 60 SD rats of experimental group.Another 30 rats without occlusion of MCA served as controls.The neurological function was determined at 2 h,24 h,3 d,7 d after the operation in all the rats,and the mortality rate were evaluated at the same time.The infarction extents in model was identified by TTC staining.Results In the experimental group,14% died after the occlusion of MCA.The neurological defect scores were significantly higher at 2 h,24 h,3 d and 7 d after the operation in the experimental group than those in the control group （P〈0.01）.It was revealed by TTC stain that there was obvious ischemic damage in the right frontoparietal lobe,part of temporal lobe and basal ganglia in the experimental group.Conclusion An ideal model of MCAO（Middle Cerebral Artery Occlusion） focal cerebral ischemia/reperfusion could be established in the rats through the improvement of some of the details in the manufacturing process.It has good stability,high reliability,high success rate,and the processe is simple.

关 键 词：脑缺血/再灌注 动物模型 动物 实验 经验 体会 大鼠 

分 类 号：R-332[医药卫生]